Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study.

Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, Chen L, Jiang M, Pan F, Zheng Y, Gao Z, Jiang B. · 2020

Read Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. by Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, Chen L, Jiang M, Pan F, Zheng Y, Gao Z, Jiang B. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7018717.txt.

Introduction

Zhang and co-authors report a 15-year follow-up study in Bone Research. Their cohort is a group of hospital staff in Beijing who caught SARS at work in 2003. Eighty staff were infected and two died. The study tracks how lung damage and hip bone death changed over the years that followed.

Seventy-one survivors completed follow-up through 2018. The team used lung scans, hip MRI, breathing tests, and questionnaires. Lung lesions shrank fast in the first year and then held steady. Most lung recovery came within two years. Hip bone death, linked to high-dose steroid treatment, also shrank early on. It then eased slowly and levelled off. The damage was not progressive, the authors conclude, and it was partly reversible.

Catalog record

CREATORZhang P, Li J, Liu H, Han N, Ju J, Kou Y, Chen L, Jiang M, Pan F, Zheng Y, Gao Z, Jiang B.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7018717

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study By Peixun Zhang, Jia Li, Huixin Liu, Na Han, Jiabao Ju, Yuhui Kou, Lei Chen, Mengxi Jiang, Feng Pan, Yali Zheng, Zhancheng Gao, Baoguo Jiang Published in: Bone Research DOI: 10.1038/s41413-020-0084-5 ABSTRACT The most severe sequelae after rehabilitation from SARS are femoral head necrosis and pulmonary fibrosis. We performed a 15-year follow-up on the lung and bone conditions of SARS patients. We evaluated the recovery from lung damage and femoral head necrosis in an observational cohort study of SARS patients using pulmonary CT scans, hip joint MRI examinations, pulmonary function tests and hip joint function questionnaires. Eighty medical staff contracted SARS in 2003. Two patients died of SARS, and 78 were enrolled in this study from August 2003 to March 2018. Seventy-one patients completed the 15-year follow-up. The percentage of pulmonary lesions on CT scans diminished from 2003 (9.40 ± 7.83)% to 2004 (3.20 ± 4.78)% (P < 0.001) and remained stable thereafter until 2018 (4.60 ± 6.37)%. Between 2006 and 2018, the proportion of patients with interstitial changes who had improved pulmonary function was lower than that of patients without lesions, as demonstrated by the one-second ratio (FEV1/FVC%, t = 2.21, P = 0.04) and mid-flow of maximum expiration (FEF25%–75%, t = 2.76, P = 0.01). The volume of femoral head necrosis decreased significantly from 2003 (38.83 ± 21.01)% to 2005 (30.38 ± 20.23)% (P = 0.000 2), then declined slowly from 2005 to 2013 (28.99 ± 20.59)% and plateaued until 2018 (25.52 ± 15.51)%. Pulmonary interstitial damage and functional decline caused by SARS mostly recovered, with a greater extent of recovery within 2 years after rehabilitation. Femoral head necrosis induced by large doses of steroid pulse therapy in SARS patients was not progressive and was partially reversible. INTRODUCTION The sudden outbreak of the severe acute respiratory syndrome (SARS) virus in early 2003 disturbed the world, especially China.1–3 Physicians and microbiologists have made great achievements in understanding the pathogen and effectively controlling its spread. The World Health Organization identified the source of the disease as SARS-CoV coronavirus on April 16, 2003.4–6 A total of 5327 individuals were diagnosed with SARS in China, and 349 patients died.7 In Beijing, SARS first broke out in Peking University People’s Hospital, where 80 medical staff contracted the virus, two of whom died subsequently. This cohort became the largest patient population worldwide and was composed of healthcare workers infected during their employment. Under the guidance on managing infectious diseases, Peking University People’s Hospital was isolated by the government for 22 days. The main clinical manifestation after infection was high fever and severe lung inflammation.5,6 The patients who survived had residual pulmonary fibrosis as well as osteonecrosis resulting from treatment with large doses of steroid pulse therapy. Several studies have investigated the long-term outcomes of recovered SARS patients, especially with respect to lung and bone damage, but no follow-up periods of more than 7 years have been reported. We conducted a comprehensive 15-year follow-up of healthcare workers with nosocomial SARS to evaluate their health utility after rehabilitation and obtain a new understanding of the associated pulmonary damage and femoral head necrosis. RESULTS Eighty health care providers at Peking University People’s Hospital contracted SARS in 2003. Two patients died of SARS in 2003, and seven patients declined to participate in the study. A total of 71 patients (57 female) completed a 15-year follow-up from 2003 to 2018 (Fig. 1).Fig. 1Flow diagram of the follow-up examinations We surveyed the length of hospital stay and treatment regimes in 2018 and evaluated health utility via questionnaires. The results showed that the length of hospital stay ranged from 10 to 70 days in 2003, with a median of 33 days (30, 42.5), and daily methylprednisolone doses ranged from 0 to 800 mg, with a median of 160 mg per day (100, 400). Only 38 patients remembered their cumulative steroid dosage (methylprednisolone via intravenous injection) ranging from 0 to 20 000 mg with a median of 3 450 mg (2 285, 5 225 mg). A total of 53 out of 71 patients were still employed in 2018, nine were retired, and nine were on long-term sick leave. The enrolled patients had various comorbidities; three patients were complicated with anxiety and depression requiring treatment, sixteen had hypertension, five had diabetes, seven had peptic ulcers, and one had Sjogren’s syndrome. The characteristics of the patients are shown in Table 1.Table 1Characteristics of the 71 SARS patients included in the final analysis in 2003CharacteristicsCategoriesN (%)General statusAge (n = 71)<3030 (42.25%)30–3928 (39.44%)40–498 (11.27%)≥505 (7.04%)Gender (n = 71)Female56 (78.87%)Male15 (21.13%)Personal medical history (n = 58)Hypertension4 (6.90%)Diabetes1 (1.72%)Sjogren’s syndrome1 (1.72%)Smoke3 (5.17%)Clinical symptoms Fever (n = 56)Yes56 (100%) Rigor (n = 57)Yes36 (63.16%) Dyspnea (n = 57)Yes35 (61.40%) Myalgia (n = 56)Yes37 (66.07%) Cough (n = 57)Yes29 (50.88%) Expectoration (n = 56)Yes10 (17.86%) Diarrhea (n = 56)Yes10 (17.86%) Anorexia (n = 56)Yes23 (41.07%) Malaise (n = 56)Yes42 (75.00%)Treatment Ribavirin (n = 52)Used46 (88.46%) MP (n = 58)Used56 (96.55%) Non-invasive ventilation (n = 45)Used14 (31.11%) Invasive ventilation (n = 58)Used1 (1.72%)Severity Lung injury (n = 71)Yes27 (38.03%) Bone injury (n = 71)Yes15 (21.13%) We performed pulmonary function tests in 2006 and 2018. The outcomes in 2006 revealed that 10 out of 46 (21.74%) patients had restrictive ventilation dysfunction. Sixteen out of 46 (34.78%) patients had reduced diffusion capacity with an ~70%–80% predicted value, indicating a mild reduction. In 2018, 15 years after being infected, we reperformed pulmonary function tests for the cohort. One out of 52 patients (1.92%) had obstructive ventilation dysfunction, while none had restrictive ventilation dysfunction. However, the number of patients with impaired FEF25%–75% values increased (16/52, 40.38%). Eighteen patients (38.46%) had reduced diffusion capacity, indicating that the ratio slightly increased, but the difference was not statistically significant. A total of 35 patients underwent pulmonary functional tests in both 2006 and 2018. The cohort was further divided into two groups (normal CT findings and abnormal CT findings group) based on their CT findings in 2003, 6 months after being infected. The pulmonary function test parameters were compared between the normal CT findings group (N = 22) and the abnormal CT findings group (N = 13). The results are shown in Table 2, and there were no substantial changes in pulmonary function in the abnormal CT finding group in the past few years. Between the two groups, only the forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC ratio) and the FEF25%–75% value were significantly reduced (P = 0.04 and P = 0.01, respectively). The other parameters, including total lung capacity (TLC) and carbon monoxide diffusing capacity of the lungs (DLCO), did not significantly change 15 years after the initial infection. The pulmonary function in 2018 was better than that in 2006 for patients whose CT scans showed no abnormalities after recovery in 2003.Table 2Comparison of pulmonary function items in 2006 and 2018 in SARS patients with or without a pulmonary CT abnormity after recovery in 2003CharacteristicsAbnormal CT (n = 13)Normal CT (n = 22)tP200620182018–2006200620182018–2006FVC/L3.57 ± 1.023.36 ± 0.98−0.20 ± 0.343.59 ± 0.673.43 ± 0.52−0.15 ± 0.360.380.703 0FVC of predicted/%102.05 ± 19.57104.54 ± 16.062.49 ± 11.1697.31 ± 14.00102.53

Read the complete text